DE69723711D1 - Aralkyl und aralkyliden heterocyclische lactame und imide - Google Patents

Aralkyl und aralkyliden heterocyclische lactame und imide

Info

Publication number
DE69723711D1
DE69723711D1 DE69723711T DE69723711T DE69723711D1 DE 69723711 D1 DE69723711 D1 DE 69723711D1 DE 69723711 T DE69723711 T DE 69723711T DE 69723711 T DE69723711 T DE 69723711T DE 69723711 D1 DE69723711 D1 DE 69723711D1
Authority
DE
Germany
Prior art keywords
aralkylides
lactame
imides
aralkyl
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69723711T
Other languages
English (en)
Other versions
DE69723711T2 (de
Inventor
Ralph Howard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69723711D1 publication Critical patent/DE69723711D1/de
Publication of DE69723711T2 publication Critical patent/DE69723711T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
DE69723711T 1996-09-30 1997-09-08 Aralkyl und aralkyliden heterocyclische lactame und imide Expired - Lifetime DE69723711T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30
US27111P 1996-09-30
PCT/IB1997/001062 WO1998014433A1 (en) 1996-09-30 1997-09-08 Aralkyl and aralkylidene heterocyclic lactams and imides

Publications (2)

Publication Number Publication Date
DE69723711D1 true DE69723711D1 (de) 2003-08-28
DE69723711T2 DE69723711T2 (de) 2004-02-05

Family

ID=21835752

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69723711T Expired - Lifetime DE69723711T2 (de) 1996-09-30 1997-09-08 Aralkyl und aralkyliden heterocyclische lactame und imide

Country Status (46)

Country Link
US (6) US6380186B1 (de)
EP (1) EP0929528B1 (de)
JP (1) JP3121355B2 (de)
KR (2) KR100346620B1 (de)
CN (2) CN1239497C (de)
AP (1) AP769A (de)
AR (1) AR008861A1 (de)
AT (1) ATE245630T1 (de)
AU (1) AU732451B2 (de)
BG (1) BG64484B1 (de)
BR (1) BR9713239A (de)
CA (1) CA2266107C (de)
CO (1) CO4650135A1 (de)
CZ (1) CZ295141B6 (de)
DE (1) DE69723711T2 (de)
DK (1) DK0929528T3 (de)
DZ (1) DZ2321A1 (de)
EA (1) EA002157B1 (de)
ES (1) ES2202634T3 (de)
GT (1) GT199700107A (de)
HK (1) HK1022313A1 (de)
HN (1) HN1997000135A (de)
HR (1) HRP970540B1 (de)
ID (1) ID19833A (de)
IL (2) IL129045A (de)
IS (1) IS4985A (de)
MA (1) MA26443A1 (de)
MY (1) MY125749A (de)
NO (1) NO313192B1 (de)
NZ (1) NZ334215A (de)
OA (1) OA11002A (de)
PA (1) PA8439101A1 (de)
PE (1) PE2799A1 (de)
PL (1) PL196005B1 (de)
PT (1) PT929528E (de)
RS (1) RS49699B (de)
SA (2) SA97180449B1 (de)
SI (1) SI0929528T1 (de)
SK (1) SK284704B6 (de)
TN (1) TNSN97161A1 (de)
TR (1) TR199900660T2 (de)
TW (1) TW491842B (de)
UA (1) UA56185C2 (de)
UY (1) UY24730A1 (de)
WO (1) WO1998014433A1 (de)
ZA (1) ZA978703B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
ATE273970T1 (de) 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
OA11722A (en) * 1998-12-02 2005-01-25 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family.
YU15500A (sh) * 1999-03-30 2002-03-18 Pfizer Products Inc. Postupak za dobijanje cikličnih tioamida
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
EP1746091A1 (de) * 2001-08-30 2007-01-24 Pfizer Products Inc. Verfahren zur Herstellung von 2-substituiertem 2-[-(4-Methylpiperazin-1-yl)-benzyliden]-thiomorpholin-3-on citrat
PT1288208E (pt) 2001-08-30 2006-09-29 Pfizer Prod Inc Processo para preparacao de compostos de 2 - (4 - alquil - 1 - piperazinil) - benzaldeido e - benzilidenilo por substituicao necleofilica aromatica de 2 - fluorobenzaldeido com 4 - alquil - 1 - piperazina em agua como solvente
JP4165882B2 (ja) * 2001-12-07 2008-10-15 ファイザー・プロダクツ・インク 治療用化合物のクエン酸塩及びその医薬組成物
AU2003214800A1 (en) * 2002-01-02 2003-07-24 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
MXPA05003366A (es) * 2002-09-30 2005-10-05 Univ California Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos.
EP1546109A4 (de) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co Hydantoinderivate als inhibitoren von matrix-metallproteinasen und/oder tnf-alpha umsetzendem enzym (tace)
WO2005053701A1 (en) * 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
JP4864719B2 (ja) * 2003-11-26 2012-02-01 ファイザー・プロダクツ・インク Ｇｓｋ−３インヒビターとしてのアミノピラゾール誘導体
CA2549308A1 (en) * 2003-12-15 2005-07-07 Pfizer Products Inc. Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
EP1737466A1 (de) * 2004-01-29 2007-01-03 Pfizer Products Inc. KOMBINATION VON Y-AMINOBUTTERSÄURE-MODULATOREN UND 5HT-1b REZEPTOR-ANTAGONISTEN
ATE533745T1 (de) * 2004-03-17 2011-12-15 Pfizer Prod Inc Neue benzyl(iden)-lactam-derivate
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
MXPA06012347A (es) * 2004-05-21 2007-01-17 Pfizer Prod Inc Derivados de pirazinilmetil-lactama.
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
WO2007026219A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
WO2007057742A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
WO2009035652A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
WO2009120803A2 (en) * 2008-03-25 2009-10-01 The Regents Of The University Of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
RS54833B1 (sr) * 2011-10-03 2016-10-31 Euroscreen Sa Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
DE102013019618A1 (de) * 2013-11-25 2015-05-28 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
EP0689536B1 (de) * 1993-03-16 2001-05-23 Pfizer Inc. Naphtalinderivate
US5556841A (en) * 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
DK0767782T3 (da) * 1994-06-29 2002-02-18 Pfizer Aryl- og heteroarylalkoxynaphthalenderivater
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (de) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinon-Verbindungen zur Behandlung von Multiple-Sklerose
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides

Also Published As

Publication number Publication date
NO991525L (no) 1999-05-28
ID19833A (id) 1998-08-06
US6627627B2 (en) 2003-09-30
US6921760B2 (en) 2005-07-26
EP0929528A1 (de) 1999-07-21
HRP970540B1 (en) 2002-08-31
KR100323167B1 (ko) 2002-02-04
IL140623A0 (en) 2002-02-10
SA97180449B1 (ar) 2005-12-21
EP0929528B1 (de) 2003-07-23
CZ107199A3 (cs) 2000-05-17
PL196005B1 (pl) 2007-11-30
ATE245630T1 (de) 2003-08-15
MY125749A (en) 2006-08-30
CO4650135A1 (es) 1998-09-03
RS49699B (sr) 2007-12-31
BR9713239A (pt) 2000-04-04
MA26443A1 (fr) 2004-12-20
TR199900660T2 (xx) 1999-07-21
PE2799A1 (es) 1999-02-04
SI0929528T1 (en) 2003-10-31
CA2266107A1 (en) 1998-04-09
AU3951497A (en) 1998-04-24
AU732451B2 (en) 2001-04-26
JP2000503679A (ja) 2000-03-28
DK0929528T3 (da) 2003-10-06
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
ES2202634T3 (es) 2004-04-01
IL129045A0 (en) 2000-02-17
CA2266107C (en) 2002-12-03
US6403592B1 (en) 2002-06-11
SA97180449A (ar) 2005-12-03
US20020147194A1 (en) 2002-10-10
CN1093123C (zh) 2002-10-23
JP3121355B2 (ja) 2000-12-25
US20020091119A1 (en) 2002-07-11
BG64484B1 (bg) 2005-04-30
NZ334215A (en) 2000-09-29
HN1997000135A (es) 1998-01-28
PA8439101A1 (es) 2000-05-24
YU16899A (sh) 2002-03-18
SK41099A3 (en) 2000-09-12
HRP970540A2 (en) 1998-08-31
SK284704B6 (sk) 2005-09-08
HK1022313A1 (en) 2000-08-04
US6562813B2 (en) 2003-05-13
CN1239497C (zh) 2006-02-01
AP9701107A0 (en) 1997-10-31
SA05260293B1 (ar) 2006-04-18
GT199700107A (es) 1999-03-23
TW491842B (en) 2002-06-21
IL140623A (en) 2005-03-20
AR008861A1 (es) 2000-02-23
US6472388B2 (en) 2002-10-29
NO313192B1 (no) 2002-08-26
DZ2321A1 (fr) 2002-12-28
NO991525D0 (no) 1999-03-29
UY24730A1 (es) 2000-09-29
WO1998014433A1 (en) 1998-04-09
PL332629A1 (en) 1999-09-27
IS4985A (is) 1999-02-26
KR100346620B1 (ko) 2002-07-26
KR20000048731A (ko) 2000-07-25
CZ295141B6 (cs) 2005-05-18
US20020091118A1 (en) 2002-07-11
CN1231661A (zh) 1999-10-13
UA56185C2 (uk) 2003-05-15
US20020091117A1 (en) 2002-07-11
DE69723711T2 (de) 2004-02-05
ZA978703B (en) 1999-03-30
CN1329002A (zh) 2002-01-02
EA199900242A1 (ru) 1999-08-26
PT929528E (pt) 2003-12-31
US6380186B1 (en) 2002-04-30
BG103297A (en) 1999-11-30
AP769A (en) 1999-09-30
IL129045A (en) 2005-09-25
EA002157B1 (ru) 2001-12-24
US20020072519A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
DE69723711D1 (de) Aralkyl und aralkyliden heterocyclische lactame und imide
NO991432D0 (no) Heterosykliske tioestere og ketoner
NO991433D0 (no) Heterosykliske estere og amider
EP0900080A4 (de) Neue indol und benzothiazolverbindungen
DE69630512D1 (de) Leistungsverstärker und kommunikationsvorrichtung
IL121298A (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their uses
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
ATE207483T1 (de) Isatinderivate als acetylcholinesterase- inhibitoren und analgetika
NO985227L (no) Alkylaminobenzothiazol og -benzoksazol - derivater
BR9708677A (pt) Piperidinas e pirrolidinas
DE69700616D1 (de) Imid derivate
NO985806D0 (no) Kitinasematerialer og fremgangsmÕter
DE69809829D1 (de) Untergrunderkennung und Kompensation
DE29616138U1 (de) Deckelauflage- und Verschließvorrichtung
DE69715979T2 (de) Chinolinderivate und ihre Anwendung
DK1042286T3 (da) Gamme-glutamyl- og beta-aspartyl-holdige immunmodulerende forbindelser og tilhørense fremgangsmåder
BR1100102A (pt) Fungicidas de quinolina e cinolina
BA97254A (bs) Ambijentalni poklopci jednodijelne dvodijelne i linijske izvedbe
NO995269D0 (no) Anvendelse av immunmodulerende midler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition